1 / 13

'Hot topics' ESSENTIAL MEDICINES FOR CHILDREN

'Hot topics' ESSENTIAL MEDICINES FOR CHILDREN. Suzanne Hill September 2006. What is the problem?. Children are therapeutic orphans Lack of appropriate clinical trials Lack of licensed medicines Lack of formulations Lack of information Initiatives so far concentrated on:

Download Presentation

'Hot topics' ESSENTIAL MEDICINES FOR CHILDREN

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 'Hot topics'ESSENTIAL MEDICINES FOR CHILDREN Suzanne Hill September 2006

  2. What is the problem? • Children are therapeutic orphans • Lack of appropriate clinical trials • Lack of licensed medicines • Lack of formulations • Lack of information • Initiatives so far concentrated on: • Developed country regulatory structures (eg FDA, EMEA) • Developed country drug information (eg BNF- C) • HIV (eg new public private partnership)

  3. For example… • Creation of a Paediatric Committee at EMEA • Requirements and Rewards/Incentives for medicinal products still under patent, orphan drugs and for off-patent medicinal products Paediatric Investigation Plans (PIP) • Other measures

  4. Patent-protected products • Obligation to submit results of studies conducted according to agreed Paediatric Investigation Plan (PIP) at time of marketing authorisation, or variation (exclude generics) If not: Invalid application for MA $: 6-month extension of the patent protection (= Supplementary Protection Certificate) • For orphan drugs, + 2 yrs market exclusivity

  5. Obvious gaps • Essential medicines list – paediatrics • Medicines for other diseases • Formulations eg fixed dose combinations for malaria, TB • Prescribing information • Market incentives for appropriate drug development • International regulatory standards, including quality • International safety monitoring and post-marketing surveillance

  6. Work so far… HIV Professor Tony Nunn, Liverpool

  7. Current work with WHO • Paediatric HIV dosing information • From - mg/kg and mg/m2 • To - agreed weight bands • with mg/m2 assigned to weight bands • Excel spreadsheets to examine closeness of fit to desired dose • limitation of • weight banding and formulation • solids preferred to liquids; half tablet? • avoiding asymmetric 2 x daily dosing • Present as ‘simple tables’

  8. Simple table abacavir

  9. What has been done so far…essential medicines • Review of current EML identifying paediatric gaps • Preliminary applications for isoniazid 50mg, pyrazinamide 150mg, phenobarbitone injection, update on caffeine • Post marketing surveillance proposal • Preliminary survey of countries about paediatric medicines, prices, guidelines, information

  10. What has been done so far….UNICEF • Global commitments include the Millennium Development Goals, 'A World Fit For Children', Unite for Children • Surveys in countries about children's access to medicines, both as part of the MICS and annual UNICEF country report • Dialogue with pharmaceutical industry around products required for Child Survival (HIV-AIDS, Malaria, ARI, diarrhoea, multimicronutrients)

  11. Plan • Work on a global project to make paediatric medicines a priority: • Add missing essential formulations to the Model list in 2007; advise on doses • Update treatment guidelines • Develop paediatric prescribing information – a formulary • Develop effective methods for provision of information at the point of care • Collaborate with regulatory authorities to encourage appropriate drug development and approval processes in all regulatory authorities • Advocate for the development of paediatric medicines by the industry • Develop quality standards for paediatric medicines • Develop a system for enhancing safety monitoring of medicines in children • Provide guidance on procurement and supply of paediatric medicines

More Related